The MiRNA Sequencing and Assay Market study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments- By Products and Services (Products, Services), By Technology (Sequencing By Synthesis, Sequencing By Oligonucleotide Ligation and Detection (SOLiD), Nanopore Sequencing, Sanger Sequencing, Single Molecule Real-time (SMRT) Sequencing), By Workflow (Library Preparation, Sequencing, Data Analysis & Storage), By Application (Cancer, Polyglutamine Diseases, Autoimmune Disease, Schizophrenia, Others), By End-User (Pharmaceutical & Biotechnology Industry, Research and Academic Institutes, Others).
MiRNA sequencing and assays are molecular techniques used to analyze microRNA (miRNA) molecules, a class of small non-coding RNA molecules involved in the regulation of gene expression. In 2024, miRNA sequencing and assays continue to be essential tools in molecular biology and biomedical research, enabling scientists to study the role of miRNAs in various biological processes, disease mechanisms, and therapeutic targets. MiRNA sequencing involves the high-throughput sequencing of miRNA molecules present in a biological sample, providing comprehensive information about miRNA expression profiles, isoforms, and sequence variations. This technique allows researchers to identify differentially expressed miRNAs associated with specific biological conditions, disease states, or treatment responses, providing insights into their functional roles and potential biomarkers. MiRNA assays utilize quantitative polymerase chain reaction (qPCR), microarray, or RNA sequencing techniques to quantify the expression levels of specific miRNAs in biological samples with high sensitivity and specificity. These assays are widely used in translational research, clinical diagnostics, and drug development to investigate the diagnostic, prognostic, and therapeutic implications of miRNA dysregulation in diseases such as cancer, cardiovascular disorders, neurological diseases, and immune disorders. With advancements in sequencing technology, bioinformatics tools, and assay platforms, miRNA sequencing and assays continue to evolve, offering increased throughput, accuracy, and cost-effectiveness for studying miRNA biology and its implications in health and disease. By providing insights into miRNA-mediated regulatory networks and disease mechanisms, miRNA sequencing and assays contribute to the discovery of novel therapeutic targets and the development of miRNA-based therapeutics for precision medicine applications.
A significant trend in the miRNA sequencing and assay market is the growing adoption of miRNA-based biomarkers in disease research. MicroRNAs (miRNAs) play crucial roles in regulating gene expression and have been increasingly recognized as potential biomarkers for various diseases, including cancer, cardiovascular disorders, and neurological conditions. Researchers are leveraging miRNA sequencing and assay technologies to profile miRNA expression patterns, identify disease-associated miRNAs, and elucidate their roles in disease pathogenesis and progression. This trend reflects a shift towards personalized medicine approaches, where miRNA biomarkers offer valuable insights into disease diagnosis, prognosis, and treatment response, driving the demand for advanced miRNA sequencing and assay platforms tailored to meet the needs of biomedical research.
A key driver for the miRNA sequencing and assay market is the continuous advancements in sequencing technologies and bioinformatics tools. The development of high-throughput sequencing platforms, such as next-generation sequencing (NGS), enables comprehensive profiling of miRNA expression with high sensitivity and accuracy. Additionally, bioinformatics tools and algorithms have become increasingly sophisticated, allowing researchers to analyze large-scale miRNA sequencing data, identify differentially expressed miRNAs, and predict their potential targets and biological functions. The synergy between sequencing technologies and bioinformatics tools empowers researchers to unravel the complexity of miRNA-mediated regulatory networks in health and disease, fueling innovation and driving adoption of miRNA sequencing and assay technologies across diverse research disciplines.
An emerging opportunity within the miRNA sequencing and assay market lies in the expansion of diagnostic and therapeutic applications in precision medicine. As our understanding of miRNA biology continues to deepen, there is growing interest in harnessing miRNAs as diagnostic biomarkers and therapeutic targets for personalized medicine approaches. MiRNA sequencing and assay technologies hold promise for identifying signature miRNA profiles associated with specific diseases, facilitating early detection, prognosis, and treatment stratification. Moreover, the development of miRNA-based therapeutics, such as miRNA mimics and inhibitors, presents novel opportunities for targeted intervention in disease pathways. By capitalizing on the potential of miRNA sequencing and assay technologies in diagnostic and therapeutic applications, stakeholders in the healthcare industry can contribute to the advancement of precision medicine paradigms and improve patient outcomes across a wide range of diseases.
Among the segments of the miRNA Sequencing and Assay Market, Nanopore Sequencing technology emerges as the fastest-growing category. This accelerated growth is propelled by several factors. Nanopore sequencing offers distinct advantages over traditional sequencing methods, including real-time detection of miRNAs with single-molecule resolution, long-read capabilities, and portability. These features make nanopore sequencing particularly well-suited for miRNA analysis in diverse applications such as cancer research, polyglutamine diseases, autoimmune diseases, and schizophrenia. Moreover, nanopore sequencing workflows, which encompass library preparation, sequencing, and data analysis, streamline the miRNA sequencing process, reducing turnaround time and enhancing efficiency. As pharmaceutical and biotechnology industries, as well as research and academic institutes, increasingly recognize the potential of nanopore sequencing for comprehensive miRNA profiling and biomarker discovery, there is a surge in the adoption of nanopore sequencing platforms and services. Additionally, ongoing advancements in nanopore sequencing technology, coupled with decreasing costs and expanding applications, further drive its rapid growth in the miRNA Sequencing and Assay Market.
The market research study provides in-depth insights into leading companies including the SWOT analyses, product profile, financial details, and recent developments acrossAbcam plc, HTG Molecular Diagnostics Inc, Illumina Inc, Lexogen GmbH, Maravai LifeSciences, Meridian Bioscience Inc, New England Biolabs Inc, Norgen Biotek Corp, PerkinElmer Inc, QIAGEN N.V., System Biosciences LLC, Takara Bio Inc, Thermo Fisher Scientific Inc
By Products and Services
Products
-Library Preparation Kits
-Sequencing Consumables
-Instruments
Services
By Technology
Sequencing By Synthesis
Sequencing By Oligonucleotide Ligation and Detection (SOLiD)
Nanopore Sequencing
Sanger Sequencing
Single Molecule Real-time (SMRT) Sequencing
By Workflow
Library Preparation
Sequencing
Data Analysis & Storage
By Application
Cancer
Polyglutamine Diseases
Autoimmune Disease
Schizophrenia
Others
By End-User
Pharmaceutical & Biotechnology Industry
Research and Academic Institutes
Others
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)
Abcam plc
HTG Molecular Diagnostics Inc
Illumina Inc
Lexogen GmbH
Maravai LifeSciences
Meridian Bioscience Inc
New England Biolabs Inc
Norgen Biotek Corp
PerkinElmer Inc
QIAGEN N.V.
System Biosciences LLC
Takara Bio Inc
Thermo Fisher Scientific Inc
• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the MiRNA Sequencing and Assay Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the MiRNA Sequencing and Assay Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.
TABLE OF CONTENTS
1 Introduction to 2024 MiRNA Sequencing and Assay Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Covered
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain
2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations
3 Executive Summary
3.1 Global MiRNA Sequencing and Assay Market Size Outlook, $ Million, 2021 to 2030
3.2 MiRNA Sequencing and Assay Market Outlook by Type, $ Million, 2021 to 2030
3.3 MiRNA Sequencing and Assay Market Outlook by Product, $ Million, 2021 to 2030
3.4 MiRNA Sequencing and Assay Market Outlook by Application, $ Million, 2021 to 2030
3.5 MiRNA Sequencing and Assay Market Outlook by Key Countries, $ Million, 2021 to 2030
4 Market Dynamics
4.1 Key Driving Forces of MiRNA Sequencing and Assay Industry
4.2 Key Market Trends in MiRNA Sequencing and Assay Industry
4.3 Potential Opportunities in MiRNA Sequencing and Assay Industry
4.4 Key Challenges in MiRNA Sequencing and Assay Industry
5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global MiRNA Sequencing and Assay Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook
6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts
7 Global MiRNA Sequencing and Assay Market Outlook by Segments
7.1 MiRNA Sequencing and Assay Market Outlook by Segments, $ Million, 2021- 2030
By Products and Services
Products
-Library Preparation Kits
-Sequencing Consumables
-Instruments
Services
By Technology
Sequencing By Synthesis
Sequencing By Oligonucleotide Ligation and Detection (SOLiD)
Nanopore Sequencing
Sanger Sequencing
Single Molecule Real-time (SMRT) Sequencing
By Workflow
Library Preparation
Sequencing
Data Analysis & Storage
By Application
Cancer
Polyglutamine Diseases
Autoimmune Disease
Schizophrenia
Others
By End-User
Pharmaceutical & Biotechnology Industry
Research and Academic Institutes
Others
8 North America MiRNA Sequencing and Assay Market Analysis and Outlook To 2030
8.1 Introduction to North America MiRNA Sequencing and Assay Markets in 2024
8.2 North America MiRNA Sequencing and Assay Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America MiRNA Sequencing and Assay Market size Outlook by Segments, 2021-2030
By Products and Services
Products
-Library Preparation Kits
-Sequencing Consumables
-Instruments
Services
By Technology
Sequencing By Synthesis
Sequencing By Oligonucleotide Ligation and Detection (SOLiD)
Nanopore Sequencing
Sanger Sequencing
Single Molecule Real-time (SMRT) Sequencing
By Workflow
Library Preparation
Sequencing
Data Analysis & Storage
By Application
Cancer
Polyglutamine Diseases
Autoimmune Disease
Schizophrenia
Others
By End-User
Pharmaceutical & Biotechnology Industry
Research and Academic Institutes
Others
9 Europe MiRNA Sequencing and Assay Market Analysis and Outlook To 2030
9.1 Introduction to Europe MiRNA Sequencing and Assay Markets in 2024
9.2 Europe MiRNA Sequencing and Assay Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe MiRNA Sequencing and Assay Market Size Outlook by Segments, 2021-2030
By Products and Services
Products
-Library Preparation Kits
-Sequencing Consumables
-Instruments
Services
By Technology
Sequencing By Synthesis
Sequencing By Oligonucleotide Ligation and Detection (SOLiD)
Nanopore Sequencing
Sanger Sequencing
Single Molecule Real-time (SMRT) Sequencing
By Workflow
Library Preparation
Sequencing
Data Analysis & Storage
By Application
Cancer
Polyglutamine Diseases
Autoimmune Disease
Schizophrenia
Others
By End-User
Pharmaceutical & Biotechnology Industry
Research and Academic Institutes
Others
10 Asia Pacific MiRNA Sequencing and Assay Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific MiRNA Sequencing and Assay Markets in 2024
10.2 Asia Pacific MiRNA Sequencing and Assay Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific MiRNA Sequencing and Assay Market size Outlook by Segments, 2021-2030
By Products and Services
Products
-Library Preparation Kits
-Sequencing Consumables
-Instruments
Services
By Technology
Sequencing By Synthesis
Sequencing By Oligonucleotide Ligation and Detection (SOLiD)
Nanopore Sequencing
Sanger Sequencing
Single Molecule Real-time (SMRT) Sequencing
By Workflow
Library Preparation
Sequencing
Data Analysis & Storage
By Application
Cancer
Polyglutamine Diseases
Autoimmune Disease
Schizophrenia
Others
By End-User
Pharmaceutical & Biotechnology Industry
Research and Academic Institutes
Others
11 South America MiRNA Sequencing and Assay Market Analysis and Outlook To 2030
11.1 Introduction to South America MiRNA Sequencing and Assay Markets in 2024
11.2 South America MiRNA Sequencing and Assay Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America MiRNA Sequencing and Assay Market size Outlook by Segments, 2021-2030
By Products and Services
Products
-Library Preparation Kits
-Sequencing Consumables
-Instruments
Services
By Technology
Sequencing By Synthesis
Sequencing By Oligonucleotide Ligation and Detection (SOLiD)
Nanopore Sequencing
Sanger Sequencing
Single Molecule Real-time (SMRT) Sequencing
By Workflow
Library Preparation
Sequencing
Data Analysis & Storage
By Application
Cancer
Polyglutamine Diseases
Autoimmune Disease
Schizophrenia
Others
By End-User
Pharmaceutical & Biotechnology Industry
Research and Academic Institutes
Others
12 Middle East and Africa MiRNA Sequencing and Assay Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa MiRNA Sequencing and Assay Markets in 2024
12.2 Middle East and Africa MiRNA Sequencing and Assay Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa MiRNA Sequencing and Assay Market size Outlook by Segments, 2021-2030
By Products and Services
Products
-Library Preparation Kits
-Sequencing Consumables
-Instruments
Services
By Technology
Sequencing By Synthesis
Sequencing By Oligonucleotide Ligation and Detection (SOLiD)
Nanopore Sequencing
Sanger Sequencing
Single Molecule Real-time (SMRT) Sequencing
By Workflow
Library Preparation
Sequencing
Data Analysis & Storage
By Application
Cancer
Polyglutamine Diseases
Autoimmune Disease
Schizophrenia
Others
By End-User
Pharmaceutical & Biotechnology Industry
Research and Academic Institutes
Others
13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Abcam plc
HTG Molecular Diagnostics Inc
Illumina Inc
Lexogen GmbH
Maravai LifeSciences
Meridian Bioscience Inc
New England Biolabs Inc
Norgen Biotek Corp
PerkinElmer Inc
QIAGEN N.V.
System Biosciences LLC
Takara Bio Inc
Thermo Fisher Scientific Inc
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise
By Products and Services
Products
-Library Preparation Kits
-Sequencing Consumables
-Instruments
Services
By Technology
Sequencing By Synthesis
Sequencing By Oligonucleotide Ligation and Detection (SOLiD)
Nanopore Sequencing
Sanger Sequencing
Single Molecule Real-time (SMRT) Sequencing
By Workflow
Library Preparation
Sequencing
Data Analysis & Storage
By Application
Cancer
Polyglutamine Diseases
Autoimmune Disease
Schizophrenia
Others
By End-User
Pharmaceutical & Biotechnology Industry
Research and Academic Institutes
Others
Countries Analyzed
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)
The global MiRNA Sequencing and Assay Market is one of the lucrative growth markets, poised to register a 12.5% growth (CAGR) between 2024 and 2030.
Emerging Markets across Asia Pacific, Europe, and Americas present robust growth prospects.
Abcam plc, HTG Molecular Diagnostics Inc, Illumina Inc, Lexogen GmbH, Maravai LifeSciences, Meridian Bioscience Inc, New England Biolabs Inc, Norgen Biotek Corp, PerkinElmer Inc, QIAGEN N.V., System Biosciences LLC, Takara Bio Inc, Thermo Fisher Scientific Inc
Base Year- 2023; Estimated Year- 2024; Historic Period- 2018-2023; Forecast period- 2024 to 2030; Currency: USD; Volume